Over the last year, Eli Lilly's (NYSE: LLY) stock is up nearly 120%. This monstrous move has helped propel the pharmaceutical leader to become the largest health care company in the world by market cap.

Although Lilly has a number of medications in its portfolio, perhaps its most popular at the moment is Mounjaro. Mounjaro is a glucagon-like peptide-1 (GLP-1) treatment for diabetes patients. It is also the primary competing product to the incredibly popular Ozempic, which was developed by Novo Nordisk.

Despite the rising popularity of GLP-1 treatments, Lilly has a lot more to offer. Let's take a deep dive into the company's entire business and understand what other catalysts could be at play.

Continue reading

Source Fool.com